[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642057":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":48,"collaborators":19,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":80,"whyStopped":19,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"GPRC5D PET\u002FCT Imaging With Comparator PET\u002FCT Studies","EXPERIMENTAL","Participants with plasma cell disorders, including multiple myeloma, will undergo GPRC5D-targeted PET\u002FCT imaging following intravenous administration of the investigational GPRC5D-targeted radiotracer. Participants will also undergo 18F-FDG PET\u002FCT and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for intra-individual head-to-head comparison of lesion detection and disease assessment. Safety, biodistribution, tracer uptake characteristics, and imaging performance will be evaluated.",[13],"Diagnostic Test: GPRC5D-Targeted PET\u002FCT Imaging",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","GPRC5D-Targeted PET\u002FCT Imaging",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Lei Kang, M.D, Ph.D","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Tingfei Dr. Gu, M.D","CONTACT","010-83572913","tingfei.gu@stx.ox.ac.uk",{"name":31,"role":27,"phone":28,"phoneExt":19,"email":32},"Zhao Chen, M.D","chenzhao0403@163.com",[34],{"facility":5,"status":19,"city":35,"state":36,"zip":19,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Beijing","Beijing Municipality","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":49,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100642057","phase-1-gprc5d-targeted-petct-imaging-in-plasma-cell-disorders-100642057",false,"NCT07660939","GPRC5D Targeted PET\u002FCT Imaging in Plasma Cell Disorders","A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET\u002FCT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders","Inclusion Criteria:\n\n* Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.\n* Healthy volunteers eligible for PET\u002FCT imaging may also be enrolled.\n* Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable.\n* Ability to undergo PET\u002FCT imaging procedures.\n* Ability to understand the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n* History of other active malignant tumors, unless considered clinically insignificant by the investigator.\n* Pregnant or breastfeeding women.\n* Inability to understand study procedures or comply with imaging examinations.\n* Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation.",true,"ALL","18 Years","80 Years",{"count":62,"type":63},50,"ESTIMATED","INTERVENTIONAL",[66],"PHASE1","This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET\u002FCT imaging in patients with plasma cell disorders, including multiple myeloma.\n\nParticipants will undergo GPRC5D-targeted PET\u002FCT, 18F-FDG PET\u002FCT, and 68Ga-BCMA PET\u002FCT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.\n\nThe study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET\u002FCT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.",[69,70],"Plasma Cell Disorders","Multiple Myeloma (MM)",[72,73,74,75,76,77,78,79],"targeted imaging","molecular imaging","GPRC5D","precise oncology","multiple myeloma","PET\u002FCT","nuclear medicine","precise diagnosis","NOT_YET_RECRUITING","2026-06-16",{"date":83,"type":84},"2026-06-22","ACTUAL",{"date":86,"type":63},"2026-06-25",{"date":88,"type":63},"2027-05-25",{"name":5,"class":6},1]